Forte Biosciences Inc (FBRX) FinancialsFBRXFinancialForte Biosciences Inc

Evaluating the bottom line, Forte Biosciences Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -62.28%, provide a clear picture of how effectively FBRX converts its operational activities into shareholder value.

In the context of the broader market, FBRX competes directly with industry leaders such as ABSI and LKFT. With a market capitalization of N/A, it holds a significant position in the sector. When comparing efficiency, FBRX's gross margin of N/A stands against ABSI's 100.00% and LKFT's 25.95%. Such benchmarking helps identify whether Forte Biosciences Inc is trading at a premium or discount relative to its financial performance.

Forte has reported significant net losses, with Q2 2026 net income at -23,331,000 USD and a forward P/E ratio of 0, indicating no earnings expected in the near term. The current ratio is strong at 10.01, suggesting good short-term financial health.